期刊文献+

用降钙素原和白细胞联合能预测心脏手术病人的感染 被引量:1

Prediction of Infection in Cardiac Surgery Patients by Combination of Procalcitonin and Leukocyte
原文传递
导出
摘要 为了探讨通过结合C反应蛋白(C-reactive protein, CRP)、白细胞(leukocyte, WBC)和降钙素原(procalcitonin, PCT)来预测大批心脏病手术患者术后感染的可行性,本研究病例对照研究涉及423例接受心肺心脏搭桥手术的心脏病患者。基于在术后期间是否有严重的败血症或化脓性休克,病人被分成两组。在重症监护病房的第1天,提取用于生物测量(PCT, CRP和WBC)的血液样本,然后每天早上提取1次,直到术后第10天。研究发现,两组群体的CRP中值类似。在10 d术后期间,感染病人群体中的WBC和PCT中值明显比未感染的群体高。高程截止≤3次(概率:4.058, 95%置信区间:2.206~7.463; p=0.001)和高程截止≥4次(概率:10.274, 95%置信区间:3.690~28.604; p<0.001),在术后第2天,随着感染的发展,PCT中值(1.7 ng/mL)和/或WBC中值(13 000个细胞/mm3)发生了明显的变化。本研究初步表明,在术后前3 d,PCT和WBC水平结合,能够预测接下来30 d心脏手术的术后感染情况,具有一定的临床应用价值。 In order to explore the feasibility of predicting postoperative infection in large number of heart surgery patients by combining C-reactive protein(CRP), leukocyte(WBC) and Procalcitonin(PCT), the case-control study of this study involved 423 patients with heart disease undergoing cardiopulmonary bypass surgery. The patients were divided into two groups based on whether they had severe sepsis or were septic shock during the postoperative period. On the first day in the intensive care unit, blood samples were extracted for biological measurements(PCT,CRP and WBC) and were extracted once every morning until the 10 thday after surgery. It was found that the CRP median of the two groups was similar. During the 10-days postoperative period, the WBC and PCT medians in the infected patients were significantlyhigher than those in the uninfected patients. Elevation cut-off ≤3 times(probability:4.058, 95% confidence interval: 2.206~7.463;p=0.001) and elevation cutoff ≥4 times(probability: 10.274, 95%confidence interval: 3.690~28.604;p<0.001). On the 2 ndday after the operation, with the development of infection,the PCT median(1.7 ng/mL) and/or WBC median(13 000 cells/mm3) had undergone significant changes. Our study preliminarily showed that the combination of PCT and WBC levels in the first 3 days after operation could effectively predict postoperative infection of cardiac surgery in the next 30 days and would have certain clinical application value.
作者 宋世卿 黄毅 Song Shiqing;Huang Yi(Chongqing Medical and Pharmaceutical College,Chongqing,401331)
出处 《基因组学与应用生物学》 CAS CSCD 北大核心 2019年第2期945-952,共8页 Genomics and Applied Biology
关键词 降钙素原 白细胞 C反应蛋白 术后感染 心脏病手术 Procalcitonin Leukocyte C-reactive protein Postoperative infection Heart surgery
  • 相关文献

参考文献1

二级参考文献45

  • 1Tan, S. J.; Kiatwuthinon, P.; Roh, Y. H.; Kahn, J. S.; Luo, D. Engineering nanocamers for siRNA delivery. Small 2011, 7, 841-856.
  • 2Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067- 1070.
  • 3Oh, Y. K.; Park, T. G. siRNA delivery systems for cancer treatment. Adv. Drug Delivery Rev. 2009, 61,850-862.
  • 4Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411,494-498.
  • 5Chen, M.; Cooper, H. M.; Zhou, J. Z.; Bartlett, P. F.; Xu, Z. P. Reduction in the size of layered double hydroxide nanoparticles enhances the efficiency of sirna delivery. 7. Colloid Interface Sci. 2013, 390, 275-281.
  • 6Tseng, Y. C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. Adv. Drug Delivery Rev. 2009, 61, 721- 731.
  • 7Li, J.; Wang, Y.; Zhu, Y.; Oupick), D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Controlled Release 2013, 172, 589-600.
  • 8Tang, F.; Li, L.; Chen, D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv. Mater. 2012, 24, 1504-1534.
  • 9Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
  • 10Ladewig, K.; Niebert, M.; Xu, Z. P.; Gray, P. P.; Lu, G. Q. M. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010, 31, 1821-1829.

共引文献5

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部